Clinical Trials Browser

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

NCT02420847 2025-11-10

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Phase 1/2 Active not recruiting

57 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT00077285 2025-11-04

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Phase 2 Active not recruiting

65 enrolled

Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

NCT04443348 2025-10-14

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

Phase 2 Active not recruiting

120 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05270057 2025-10-09

LONCA

Phase 1 Active not recruiting

11 enrolled

Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

NCT04479267 2025-09-29

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Phase 2 Active not recruiting

8 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00295893 2025-09-25

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Phase 2 Active not recruiting

121 enrolled 10 charts

Breast

Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

NCT03004287 2025-09-10

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Phase 2 Active not recruiting

50 enrolled

Plasma cell

Multiple Myeloma

NCT04243616 2025-09-05

CemiHALT

Phase 2 Active not recruiting

36 enrolled

Breast

Invasive Breast Cancer

NCT02957968 2025-08-28

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Phase 2 Active not recruiting

46 enrolled 21 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03505762 2025-08-20

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

Phase 2 Active not recruiting

80 enrolled

Lymphoid

Lymphoma, B-Cell

NCT02734771 2025-08-12

BV mini CHP

Phase 2 Active not recruiting

24 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04546620 2025-08-06

REMoDL-A

Phase 2 Active not recruiting

453 enrolled

Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04947501 2025-08-05

A Study of N9 Chemotherapy in Children With Neuroblastoma

Phase EARLY_PHASE1 Active not recruiting

26 enrolled

CNS

Neoplasms, Neuroblastoma

NCT05275777 2025-07-25

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Phase 1/2 Active not recruiting

66 enrolled

BreastOther solid neoplasm

HER2-negative Breast Cancer

Clinical Trials

Bevacizumab/Doxorubicin/Radiation for Sarcoma

Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Lurbinectedin + Doxorubicin In Leiomyosarcoma

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

CARABELA

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer

Split-Dose R-CHOP for Older Adults With DLBCL

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

Mature B-Cell Lymphoma And Leukemia Study III

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

FIL_PTCL13

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)

LONCA

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

CemiHALT

Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca

Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment

BV mini CHP

REMoDL-A

A Study of N9 Chemotherapy in Children With Neuroblastoma

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer